morpholinoanthracycline mx2 has been researched along with Benign Neoplasms, Brain in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kabuto, M; Kitai, R; Kobayashi, H; Kubota, T; Nakagawa, T | 1 |
| Kaoru, K; Katsuzo, K; Tohru, U; Yasunori, K; Yuki, K | 1 |
| Ariyoshi, Y; Ogawa, M | 1 |
| Fujita, H; Kawamoto, K; Kiya, K; Kurisu, K; Ogasawara, H; Shinkai, H; Sugiyama, K; Uozumi, T | 1 |
| Arita, N; Hayakawa, T; Kuratsu, J; Kurisu, K; Uozumi, T; Ushio, Y | 1 |
| Bartlett, J; Basser, RL; Byrne, M; Cher, L; Clarke, K; Dalley, D; Findlay, M; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Mitchell, P; Pell, M; Underhill, C | 1 |
| Hill, JS; Kaye, AH; Park, SJ | 1 |
| Arita, N; Kayama, T; Kubo, N; Kuratsu, JI; Mori, T; Sawamura, Y; Ushio, Y | 1 |
| Furuta, T; Matsumoto, K; Mizumatsu, S; Ohmoto, T; Ono, Y; Tamiya, T | 1 |
| Mima, T; Mori, K; Mostafa, MG | 1 |
| Arita, N; Hayakawa, T; Izumoto, S; Komeshima, N; Mogami, H; Ohnishi, T; Oku, Y; Taki, T; Ushio, Y; Yamamoto, H | 1 |
1 review(s) available for morpholinoanthracycline mx2 and Benign Neoplasms, Brain
| Article | Year |
|---|---|
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
4 trial(s) available for morpholinoanthracycline mx2 and Benign Neoplasms, Brain
| Article | Year |
|---|---|
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Brain Neoplasms; Carubicin; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local | 1999 |
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Carubicin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis | 1999 |
Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Topics: Adult; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Cardiomyopathies; Carubicin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Glioblastoma; Humans; Leukopenia; Male; Middle Aged; Nausea; Oligodendroglioma; Treatment Outcome; Vomiting | 2000 |
7 other study(ies) available for morpholinoanthracycline mx2 and Benign Neoplasms, Brain
| Article | Year |
|---|---|
The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Brain Neoplasms; Carubicin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Glioma; Humans; Male; Microscopy, Electron; Neoplasm Transplantation; Rats; Rats, Wistar; Subcellular Fractions; Tissue Distribution; Tumor Cells, Cultured | 1995 |
[Antitumor effect of KRN 8602 for malignant brain tumors using collagen gel matrix assay].
Topics: Animals; Antibiotics, Antineoplastic; Brain Neoplasms; Carubicin; Collagen; Drug Screening Assays, Antitumor; Gels; Glioblastoma; Humans; Medulloblastoma; Mice; Neoplasm Transplantation; Tumor Cells, Cultured | 1995 |
[Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Topics: Animals; Antibiotics, Antineoplastic; Brain; Brain Neoplasms; Carubicin; Cell Division; Female; Glioma; Neoplasm Transplantation; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1993 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carubicin; Cell Division; Glioma; Humans; Lipoproteins; Rats; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Carubicin; Dose-Response Relationship, Drug; Feasibility Studies; Glioma; Injections, Intraventricular; Injections, Spinal; Male; Nervous System Diseases; Rats; Rats, Wistar; Survival Analysis | 2000 |
Antitumor effect and peritumoral brain edema formation in relation to MX2, ACNU, and doxorubicin therapy: a comparative analysis using rodent models of gliomas.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Brain Edema; Brain Neoplasms; Carubicin; Disease Models, Animal; Doxorubicin; Glioma; Leukocyte Count; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nimustine; Rats; Survival Rate | 2000 |
[Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
Topics: Animals; Antibiotics, Antineoplastic; Arachnoid; Brain Neoplasms; Carubicin; Female; Glioma; Humans; Meningeal Neoplasms; Naphthacenes; Pia Mater; Rats; Rats, Inbred Strains | 1988 |